Published in Med Decis Making on December 22, 2014
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ (2005) 2.52
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm (2011) 2.25
Management of Group A beta-hemolytic streptococcal pharyngitis. Am Fam Physician (2001) 2.22
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective. Value Health (2013) 2.10
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 2.04
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke. Stroke (2011) 1.72
The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med (1999) 1.60
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J (2014) 1.54
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis (2012) 1.40
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke (2013) 1.37
Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. Appl Health Econ Health Policy (2013) 1.32
A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health (2011) 1.24
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. J Eval Clin Pract (2010) 1.05
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One (2012) 0.99
Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol (2011) 0.98
Cost implications of new treatments for advanced colorectal cancer. Cancer (2009) 0.96
Reducing the "pill burden". CMAJ (2012) 0.95
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol (2007) 0.95
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence (2013) 0.94
Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res (2010) 0.93
Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Clin Ther (2012) 0.88
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone (2010) 0.88
Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst (2013) 0.87
Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin (2009) 0.86
Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer. Med Decis Making (2013) 0.84
Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. Am J Cardiol (2012) 0.84
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health (2011) 0.84
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ (2012) 0.83
What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm (2010) 0.83
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics (2010) 0.83
Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? NHPF Issue Brief (2002) 0.82
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Clin Ther (2010) 0.82
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics (2010) 0.81
Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care (2012) 0.81
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS (2012) 0.81
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics (2010) 0.80
Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Clin Ther (2012) 0.80
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics (2012) 0.80
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Clin Ther (2013) 0.80
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ (2011) 0.79
A cost-effectiveness analysis of anal cancer screening in HIV-positive women. J Low Genit Tract Dis (2012) 0.79
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Clin Breast Cancer (2012) 0.78
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ (2012) 0.78
Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. Am J Manag Care (2013) 0.77
Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy. J Oncol Pharm Pract (2012) 0.77
Beyond AWP . . . way beyond. Value Health (2009) 0.76